Impact of Infant Nutritional Status on Outcomes in Lung Transplant

Abstract

a significant decrease in median IL-6 levels pg/mL (pre 1.3 (1.1-1.7); post 1.2 (0.8-1.4), p= 0.037) and possible improvements in self-reported dyspnea (ES= 0.23, p= 0.17), depressive symptoms (ES= 0.26, p= 0.07) and HRQOL (ES= 0.40, p= 0.13) post intervention. Conclusion: Eight weeks of slow-paced respiration therapy was feasible and associated with a significant decrease in IL-6 levels and possible improvements in sleep disturbance, dyspnea, depressive symptoms and HRQOL. A larger randomized clinical trial is needed to determine if slow-paced respiration therapy is effective in PAH.